Transradial Access Products - Market Insights, Competitive Landscape, and Market Forecast - 2032

Transradial Access Products Market by Product (Catheter, Guidewire, Sheath, and Others), Application (Diagnostic & Interventional, Drug Administration, Blood Transfusion, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2032 owing to the increasing instances of cardiovascular conditions and growing technological advancements in these devices globally.

The transradial access products market was valued at USD 2.39 billion in 2024, growing at a CAGR of 7.20% during the forecast period from 2025 to 2032 to reach USD 4.15 billion by 2032. The transradial access products market is experiencing notable growth, primarily driven by the increasing instances of cardiovascular conditions such as coronary artery disease (CAD) and peripheral artery disease (PAD). This surge is further fueled by the increasing prevalence of risk factors associated with cardiovascular diseases, including hypertension, diabetes, obesity, and smoking, which are contributing to a higher demand for interventional procedures. In addition, continuous technological advancements in transradial access devices and growing adoption of radial access techniques in pediatric patients are the factors that are expected to significantly drive the demand for transradial access products during the forecast period from 2025 to 2032.

Transradial Access Products Market Dynamics:

According to the data from the American College of Cardiology Foundation (2024), stated that, in 2022, an estimated 315 million people globally were living with coronary artery disease (CAD). The same source further stated that among global regions, Central Europe, Eastern Europe, and Central Asia recorded the highest age-standardized prevalence in 2022, with 8,019 cases per 100,000, while South Asia reported the lowest at 2,393 per 100,000 (range: 1,746 to 3,188).

As per data from the American Heart Association (2023), it was reported that PAD affected approximately 200 million individuals globally.

These rising figures reflect a growing burden of cardiovascular diseases, which in turn drives the need for more frequent diagnostic and interventional procedures, such as coronary angiography and percutaneous coronary interventions (PCI). Transradial access is increasingly being adopted as the preferred approach for these procedures due to its minimally invasive nature, lower complication rates, and improved patient outcomes compared to traditional femoral access. As a result, the high and growing global cases of CAD and PAD are directly accelerating the demand for advanced transradial access devices to support safe, effective, and patient-friendly vascular interventions.

Furthermore, the growing incidence of key risk factors for cardiovascular diseases, such as hypertension, diabetes, obesity, and smoking, is significantly driving the demand for interventional procedures. This, in turn, is fueling the growth of the transradial access products market, as healthcare providers increasingly adopt minimally invasive approaches for cardiovascular interventions. For example, according to the World Health Organization (2023), approximately 1.28 billion adults aged 30 to 79 worldwide were affected by hypertension, underscoring the vast patient population requiring ongoing diagnostic and therapeutic vascular procedures where transradial access offers safer and more efficient outcomes.

Additionally, product development activities among key market players in the transradial access products market is further expected to boost the overall market growth. For instance, in December 2024, Hangzhou Revita Medical Technology Co., Ltd., a subsidiary of MEDNOVO Group, received Class III medical device approval from the National Medical Products Administration (NMPA) for its independently developed SUIZHI® Radial Access Guide Catheter.

Therefore, the factors stated above collectively will drive the overall transradial access products market during the forecast period from 2025 to 2032.

However, the risk and complication associated with these devices, and others, may limit their end-user base, thus acting as key constraints limiting the growth of the transradial access products.

Transradial Access Products Market Segment Analysis:

Transradial Access Products Market by Product (Catheter, Guidewire, Sheath, and Others), Application (Diagnostic & Interventional, Drug Administration, Blood Transfusion, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the products segment of transradial access products, the catheter category is expected to have a significant revenue share in the year 2024. The market for the catheter category within transradial access products is witnessing steady growth, due to their critical role in diagnostic and interventional cardiovascular procedures. Catheters are essential for navigating the vascular system, delivering contrast media, and deploying therapeutic devices during procedures such as coronary angiography, percutaneous coronary intervention (PCI), and neurovascular interventions. Also, their adoption is largely due to advancements in design, such as hydrophilic coatings for smoother insertion, improved torque control for precise navigation, and compatibility with smaller radial arteries. These features enhance procedural efficiency and patient comfort, making catheters a preferred choice in transradial approaches.

Also, rising approvals and launches related to catheter-related transradial access products are projected to exhibit the fastest growth during the forecast period. For instance, in January 2024, AngioDynamics, Inc., a prominent medical technology company dedicated to enhancing vascular health, announced that the U.S. Food and Drug Administration (FDA) granted clearance for its Auryon XL Catheter. This 225-cm radial access catheter was approved for use with the Auryon atherectomy system in the treatment of PAD.

Therefore, owing to all the above-mentioned factors, the demand for the catheter is expected to witness considerable growth, eventually contributing to the overall growth of the transradial access products market during the forecast period from 2025 to 2032.

North America is expected to dominate the overall transradial access products market:

Among all the regions, North America is expected to dominate the transradial access products market in the year 2024. This regional dominance is largely attributed to the growing instances of cardiovascular conditions, notably CAD, along with a surge in comorbidities such as hypertension and hyperlipidemia, which are driving the need for interventional procedures. Additionally, continuous advancement in product innovation, an increase in regulatory approvals, and the presence of a robust and technologically advanced healthcare infrastructure further reinforce the region's strong position. These factors are expected to sustain and accelerate the growth of the transradial access products market throughout the forecast period from 2025 to 2032.

According to the National Institutes of Health (2023), an estimated 20.5 million people in the U.S. were living with CAD, highlighting a substantial patient population requiring interventional procedures such as angioplasty and stenting. These are some of the key areas where transradial access is widely adopted due to its lower complication rates and quicker recovery compared to the traditional femoral approach.

Moreover, heart disease continues to be a major cause of morbidity, including conditions like acute coronary syndrome, atherosclerosis, and congestive heart failure. The growing prevalence of these conditions, along with the fact that nearly 47% of the U.S. population had at least one major risk factor such as high cholesterol, hypertension, or smoking, indicates a sustained and rising need for diagnostic and interventional cardiovascular procedures. In this context, transradial access products play a vital role, providing a safer, less invasive, and more patient-centric alternative to traditional access methods.

Internationally, the trend is mirrored in Canada, where the Canadian Institute for Health Information (2024) reported that 2.4 million individuals were living with heart disease in 2022. This further reflected a broader North American demand for advanced cardiovascular interventions. As hospitals and cardiology centers continue to shift toward minimally invasive techniques with improved patient outcomes and lower hospital stay durations, the adoption of transradial access products is expected to rise steadily, aligning with the growing cardiovascular disease burden across the region.

However, the rising product launches and commercialization agreements among key manufacturers and other companies are anticipated to boost the market. For instance, in December 2024, Terumo Interventional Systems (TIS), a division of Terumo Corporation, announced the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company’s radial-to-peripheral (R2P) portfolio. The R2P NaviCross catheter, available in a 200 cm length, was designed to optimize performance in R2P procedures. Its double-braided, stainless-steel construction was engineered to provide superior trackability and torque control for lesion crossing in complex procedures.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American region in the transradial access products market.

Transradial Access Products Market key players:

Some of the key market players operating in the transradial access products market include AngioDynamics, Terumo Medical Corporation, Medtronic, SCW Medicath Ltd., Tianck Medical Co., Ltd., Edwards Lifesciences Corporation, Shanghai Kindly Medical Instruments Co., Ltd., Colibri Heart Valve, Merit Medical Systems, Nipro Medical Corporation, Boston Scientific Corporation, Cordis, Beijing Demax Medical Technology Co., Ltd., BD, Teleflex Incorporated, and others.

Recent Developmental Activities in the Transradial Access Products Market:

• In June 2024, BioCardia, Inc., a company specializing in cellular and cell-derived therapies for cardiovascular and pulmonary conditions, announced that the United States Patent and Trademark Office issued Patent No. 11,986,611, titled “Radial and Transendocardial Delivery Catheter.” The patent is set to remain in effect until 2036.
• In November 2022, Merit Medical announced the launch of the PreludeSync EZ radial compression device, which was designed to provide precise two-handed placement and clear visibility of the access site. The product was developed to optimize bleeding prevention for radial artery procedures.

Key takeaways from the transradial access products market report study

• Market size analysis for the current transradial access products market size (2024), and market forecast over 8 years (2025 to 2032)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the transradial access products market
• Various opportunities available for the other competitors in the transradial access products market space
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current transradial access products market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for transradial access products market growth in the future?

Target audience who can benefit from this transradial access products market report study

• Transradial access products providers
• Research organizations and consulting companies
• Transradial access products-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in transradial access products
• Various end-users who want to know more about the transradial access products market and the latest developments in the transradial access products market

Frequently Asked Questions for the Transradial Access Products Market:

1. What are transradial access products?

• The transradial access products are tools that are used for percutaneous coronary intervention and coronary angiography. Transradial access is required for a catheterization procedure performed for the diagnosis and treatment of arterial diseases.

2. What is the market for transradial access products?

• The transradial access products market was valued at USD 2.39 billion in 2024, growing at a CAGR of 7.20% during the forecast period from 2025 to 2032 to reach USD 4.15 billion by 2032.

3. What are the drivers for the transradial access products market?

• The transradial access products market is experiencing notable growth, primarily driven by the increasing instances of cardiovascular conditions such as coronary artery disease (CAD) and peripheral artery disease (PAD). This surge is further fueled by the increasing prevalence of risk factors associated with cardiovascular diseases, including hypertension, diabetes, obesity, and smoking, which are contributing to a higher demand for interventional procedures. In addition, continuous technological advancements in transradial access devices and growing adoption of radial access techniques in pediatric patients are the factors that are expected to significantly drive the demand for transradial access products during the forecast period from 2025 to 2032.

4. Who are the key players operating in the transradial access products market?

• Some of the key market players operating in the transradial access products market include AngioDynamics, Terumo Medical Corporation, Medtronic, SCW Medicath Ltd, Tianck Medical Co., Ltd., Edwards Lifesciences Corporation, Shanghai Kindly Medical Instruments Co., Ltd., Colibri Heart Valve, Merit Medical Systems, Nipro Medical Corporation, Boston Scientific Corporation, Cordis, Beijing Demax Medical Technology Co., Ltd., BD, Teleflex Incorporated, and others.

5. Which region has the highest share in the transradial access products market?

• Among all the regions, North America is expected to dominate the transradial access products market in the year 2024. This regional dominance is largely attributed to the growing instances of cardiovascular conditions, notably CAD, along with a surge in comorbidities such as hypertension and hyperlipidemia, which are driving the need for interventional procedures. Additionally, continuous advancement in product innovation, an increase in regulatory approvals, and the presence of a robust and technologically advanced healthcare infrastructure further reinforce the region's strong position. These factors are expected to sustain and accelerate the growth of the transradial access products market throughout the forecast period from 2025 to 2032.

This product will be delivered within 2 business days.